Concepedia

Sodium-Glucose Co-Transporter-2 Inhibitors and Cardiac Outcomes Among Patients Treated With Anthracyclines

Carlos A. Gongora, Zsófia D. Drobni, Thiago Quinaglia Araujo Costa Silva, Amna Zafar, Jingyi Gong, Daniel A. Zlotoff, Hannah Gilman, Sarah Hartmann, Supraja Sama, Sofia Nikolaidou,

JACC Heart Failure · 2022 · 155 citations · 19 references

DOIFull text

Open access

Concepts

References

19

Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction

John J.V. McMurray, Scott D. Solomon, Silvio E. Inzucchi et al. · New England Journal of Medicine · 2019 · 6.9K citations · Full text

, , +14

The SGLT-2 inhibitor empagliflozin improves myocardial strain, reduces cardiac fibrosis and pro-inflammatory cytokines in non-diabetic mice treated with doxorubicin

Vincenzo Quagliariello, Michelino De Laurentiis, Domenica Rea et al. · Cardiovascular Diabetology · 2021 · 364 citations · Full text

, , +17

The diabetes medication Canagliflozin reduces cancer cell proliferation by inhibiting mitochondrial complex-I supported respiration

Linda A. Villani, Brennan K. Smith, Katarina Marcinko et al. · Molecular Metabolism · 2016 · 244 citations · Full text

, , +17

Sodium–glucose cotransporter 2 inhibitor Dapagliflozin attenuates diabetic cardiomyopathy

Mohamad Arow, Maayan Waldman, Dor Yadin et al. · Cardiovascular Diabetology · 2020 · 228 citations · Full text

, , +17

AMPK/PGC1α activation by melatonin attenuates acute doxorubicin cardiotoxicity via alleviating mitochondrial oxidative damage and apoptosis

Dong Liu, Zhiqiang Ma, Shouyin Di et al. · Free Radical Biology and Medicine · 2018 · 228 citations

, , +17